Soar Biodynamics, Inc.
Soar Through Life™

The Prostate Cancer Screening Problem

Prostate cancer screening using PSA tests is problematic and controversial. There are too many unwarranted biopsies and too much over-treatment. At the same time too many men die from prostate cancer because of late detection and treatment.

The U.S. Preventative Services Task Force has recommended stopping the use of PSA for routine screening. Other major medical organizations disagree. Currently, the choice is between screening poorly and don’t screen.

Home

 

At Soar BioDynamics, Inc., we have developed a powerful new way to screen for prostate cancer. Our Dynamic Screening for prostate cancer Clinical Decision Support System uses sophisticated analysis of: a man’s PSA history, differential analysis for prostatitis and BPH and other information. Preliminary results on retrospective populations suggest a breakthrough. We are developing validation studies with two large medical systems with long data histories for over 3 million men combined. We expect to have our first large scale validation results later in 2012 with comprehensive results in 2013.

 

Home Overview News The Team Contact Us